GU medical oncologist, Associate Professor of Medicine, and clinical researcher at Duke Cancer Institute. All tweets and views my own.
Durham, NC
Joined May 2015
- Tweets500
- Following528
- Followers727
- Likes1.5K
Michael Harrison retweeted
Fantastic event and opportunity for anyone impacted by GU cancers to learn, meet with our @DukeGUCancer team, and interact with others who are facing similar battles in our community. Looking forward to being involved and seeing a great crowd as usual.
@DukeCancer @DukeHealth @Daniel_J_George @AarmstrongDuke
Come learn about latest treatments for #prostatecancer #kidneycancer #bladdercancer. Free for people living with cancer & caregivers. Thanks to friends who provided scholarships.
When: Sept 19
Register/get details:
duke.is/GUCommunityEducation…
@AarmstrongDuke
Michael Harrison retweeted
Triplets are an uphill battle if you choose a potent IO/TKI combo as the comparator.
Nivo/Ipi is actually the doublet to beat for drug development. Cosmic 313 suffered from choosing the wrong TKI, Litespark 012 from its design.
There is still room for triplets..
JUST IN: LITESPARK-012 did not meet its dual primary endpoints of PFS and OS versus pembrolizumab + lenvatinib in frontline advanced ccRCC. A disappointing result, but an important one. Carefully conducted negative trials still move the field forward by challenging assumptions, informing future strategy, and helping us avoid adding complexity without clear patient benefit.
merck.com/news/merck-and-eis…
Michael Harrison retweeted
🆕article in press: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial @DrChoueiri
doi.org/10.1016/j.annonc.202…
Nice one table summary by @brian_rini putting today’s LITESPARK-011 results (presented just now @GU26) in context. @Uromigos @DukeCancer
Michael Harrison retweeted
In a 12-week, telehealth-delivered program, higher adherence (≥6 weeks) significantly improved QOL (FACT-G), w fatigue reduction mediating the benefit @PauloBergerot @ASCO #GU26
Importantly, effects were consistent across prostate, kidney, & bladder cancers and treatment types
Michael Harrison retweeted
Big day in the poster hall for our group! @DocHariKris and I shared 6 posters today spanning cardio-oncology + multi-omics in prostate cancer: connecting imaging, adiposity, immune remodeling, proteomics, and cardio–kidney–metabolic (CKM) risk. @TarekNahle @neerajaiims @GACancerCenter @anantm
Poster lineup:
•T1 MRI / radiomics: Skeletal muscle radiomic features on prostate T1-weighted MRI and association with major adverse cardiac events (MACE) @anantm
•Obesity-associated epigenetic remodeling under androgen deprivation therapy (ADT) and implications for cardiometabolic risk @ImmunologyAU
•CyTOF: CyTOF immune profiling: how obesity shapes biphasic immune remodeling (CD45+ circulating cells) during ADT @ImmunologyAU
•Proteomics: Proteomic remodeling after ADT: how age modifies innate immune/complement–ECM pathways @mayo
•CardioKidneyMetabolic Syndrome: CKM syndrome stages in prostate cancer and prognostic significance for CV morbidity/mortality
•MRI T2 microenvironment: Periprostatic adipose microenvironment remodeling in aggressive prostate cancer (atlas-based geometric analysis) @anantm
Really appreciated all the thoughtful questions and conversations: always energizing to share the work and hear new perspectives. If you’re here, come say hi!
#ProstateCancer #CardioOncology #Radiomics #Epigenetics #CyTOF #Proteomics #CKM #CancerResearch #TranslationalScience #GU26 @ASCOPost @ASCO @OelsayedMD @EmoryAIHumanity . All abstracts out in @JCO_ASCO . Thanks to @CDMRP and @AHAScience for funding our work.
Michael Harrison retweeted
Congratulations on this to my colleague Chris Hoimes. @DukeGUCancer @DukeCancer
Big day for #bladdercancer at #GU26 kicks off with much anticipated KNB15/EV304 trial for periop EV plus pembro vs neoadjuvant gem/cisplatin in MIBC. Significant improvements in both EFS and OS (HR 0.65) with pCR 55 vs 32% favoring EV-P. New SOC for #MIBC!
Next questions: How much adjuvant therapy is truly needed? Can we spare surgery for carefully selected patients? ctDNA/utDNA may help answer in the coming years.
@OncoAlert @OncLive @GUOncologyNow @MattGalsky @DrChrisHoimes @BladderCancerUS
Michael Harrison retweeted
PCWG4 is published! #GU26 Thanks to @ThePCCTC and my co chairs Howard Scher and Mike Morrison and the 65 co-authors of these new trial guidelines! @DukeCancer @JCO_ASCO ascopubs.org/doi/10.1200/JCO…
Michael Harrison retweeted
Just Published at @JCO_ASCO and out for #GU26
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
ascopubs.org/doi/10.1200/JCO…
Here is Dr Andrew Armstrong🇺🇸 @AarmstrongDuke to tell us more #ProstateCancer
@DrRanaMcKay
Michael J. Morris
@EAntonarakis
@mishabeltran
@drlouiseemmett
@ProfKHerrmann
@DrMHofman
@JoshLangMD
@CaPsurvivorship
@Cpaller
@cnsternberg
Michael Harrison retweeted
Does infusion timing impact immunotherapy outcomes? 🎧
Tom, Brian, and Dr. David McDermott debate a recent Nature Medicine paper on immune therapy timing in lung cancer—covering methodology, plausibility, and the need for prospective trials.
Listen now!
🔗 GuOncology Now: buff.ly/1RuWI1T
🎧 Apple Podcasts: buff.ly/ekl8nuP
🎧 Spotify: buff.ly/e6baUB5
#Uromigos #GUOncology
Michael Harrison retweeted
#TaraSeibert killing it at her first #GU26. She starts her oncology fellowship at @DukeCancer in July. @AarmstrongDuke and @Hannahdzmd have been her mentors. Help us recruit her to GU!
Michael Harrison retweeted
The breakout session on optimizing care for older adults w cancer was a powerful reminder that geriatric principles belong at the center of oncology care @ASCO #GU26
@drjefstathiou @spsutkaMD @kgsindhu @Tullika_Garg @HannaHunterMD
Michael Harrison retweeted
How many of you assess your patients’ physical capacity before an oncologic procedure?
Outstanding talk by @spsutkaMD on frailty and how exercise can truly impact our patients’ prognosis.
#GU26
Very clear and cogent explanation of PCWG4 guidelines (just published!) by my friend and colleague @AarmstrongDuke @GU26
General session on Tx Selection, Response Assessment and Monitoring in Advanced Prostate Cancer @GU26 starting now! I wore my Duke socks.
It’s almost showtime! Oral Abstract Session A: Prostate Cancer is about to kickoff #GU26
Michael Harrison retweeted
@hannahdzmd highlighting combos w #PSMAlutetium — We are doing combo w ONC-392 @utswcancer!
New IIT @DukeGUCancer w/ cabozantinib & lutetium in metastatic #prostatecancer. IITs are hard to open — kudos to the team @MRHarrisonMD @Daniel_J_George @AarmstrongDuke! @DAVAOnc #DAVAGU
I would happily wear this t-shirt! @fitaftercancer
I appreciate @Uromigos getting down to brass tacks as to how trial data affects day to day clinical GU practice! Great insights from community oncology colleagues. @GUconference #WorldGU24
#WorldGU24 An amazing session with The @Uromigos @tompowles1 @brian_rini with community oncologists to discuss the real world practice patterns in GU cancers.
